Recent Updates
Recently added Catalysts

Diffuse Cutaneous Systemic Sclerosis: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$101Muniverse median $1.20B
Allocated capital$51M$101M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank288/299crowding rank 288

Diffuse Cutaneous Systemic Sclerosis is uncontested. Cumberland Pharmaceuticals (CPIX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Ifetroban in phase 2.

There is no public comparable to price it against. CPIX spreads its $101M market cap across 2 indications, so $51M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$51M of allocated capital sits in Diffuse Cutaneous Systemic Sclerosis, ranking it 288th of 299 indications by the money committed to it.

Companies developing drugs for Diffuse Cutaneous Systemic Sclerosis 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CPIXCumberland PharmaceuticalsIfetrobanPhase 21$101MNo2No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Diffuse Cutaneous Systemic Sclerosis counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Diffuse Cutaneous Systemic Sclerosis has one competitor and a median of $101M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

COPD Exacerbation1 company · $61M · median $122MUncontestedChildhood-onset Systemic Lupus Erythematosus1 company · $69M · median $276MUncontestedAcute Respiratory Distress Syndrome1 company · $136M · median $272MUncontestedPemphigus1 company · $148M · median $590MUncontestedCOPD1 company · $167M · median $333MUncontestedPrevention of Acute Rejection in Renal Transplant1 company · $226M · median $226MUncontestedOsteoarthritis Patients Scheduled for Total Knee Replacement Surgery1 company · $265M · median $1.1BUncontestedIdiopathic Membranous Nephropathy1 company · $279M · median $838MUncontested

Diffuse Cutaneous Systemic Sclerosis pipeline questions

Which biotech companies are developing drugs for Diffuse Cutaneous Systemic Sclerosis?

Cumberland Pharmaceuticals (CPIX, Ifetroban, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Diffuse Cutaneous Systemic Sclerosis.

How advanced is the Diffuse Cutaneous Systemic Sclerosis pipeline?

Of the 1 clinical-stage programme in Diffuse Cutaneous Systemic Sclerosis, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Diffuse Cutaneous Systemic Sclerosis?

No. CPIX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Diffuse Cutaneous Systemic Sclerosis, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map